Verrica Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis
Verrica Pharmaceuticals Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical validation across multiple indications, strengthened balance sheet, and demonstrated commercialization progress position Verrica for significant near-term catalysts. Verrica has reported a series of clinical, regulatory and financing milestones, including positive EMA feedback supporting a YCANTH MAA without additional Phase 3 trials in October 2025, strong VP-315 Phase 2.
What is Verrica Pharmaceuticals Inc.'s industry? Verrica Pharmaceuticals Inc. (verrica.com) operates in Dermatology Therapeutics / Specialty Pharmaceuticals. AskCyborg classifies Verrica Pharmaceuticals Inc. under Dermatology Therapeutics / Specialty Pharmaceuticals in its company registry.
Verrica Pharmaceuticals is a dermatology therapeutics company engaged in the development and sale of medications for the treatment of skin diseases in the United States. YCANTH (VP-102) is the first and only healthcar...
Cyborg Score thesis
Clinical validation across multiple indications, strengthened balance sheet, and demonstrated commercialization progress position...
Read the full analyst-debate transcript →Get the Latest Verrica Pharmaceuticals Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVerrica Pharmaceuticals Inc. Overview
Pro stress-test →Verrica Pharmaceuticals is a dermatology therapeutics company engaged in the development and sale of medications for the treatment of skin diseases in the United States. YCANTH (VP-102) is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States. The company is capitalizing on significant unmet medical needs with an expanding pipeline and recent international expansion.
Strategic Profile
Pro stress-test →YCANTH is in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. The company is positioned as a focused dermatology player with blockbuster potential across multiple viral skin conditions and oncologic indications.
Competitive Landscape
Pro stress-test →Verrica operates in the dermatology therapeutics space with minimal direct competition for YCANTH in molluscum contagiosum. The common warts market is a multibillion-dollar opportunity with no FDA-approved prescription therapies, positioning Verrica as a potential pioneer. In oncologic dermatology with VP-315, the company competes in a broader field of skin cancer treatments.
Industry Context
Verrica Pharmaceuticals Inc. operates in Dermatology Therapeutics / Specialty Pharmaceuticals.
Key facts
Headquarters: West Chester, Pennsylvania, United States · Revenue: $14.3M (Q3 2025)